Prenylamine

Summary

Prenylamine (CHEMBL24072) is an approved small molecule (ATC C01DX02); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01DX02 (+1 more)
• Indications: 1 condition
• Chemistry: 329.5 Da · C24H27N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL24072
Name	Prenylamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9801
ATC	C01DX02, C01DX52
Molecular formula	C24H27N
Molecular weight	329.5
InChIKey	IFFPICMESYHZPQ-UHFFFAOYSA-N

SMILES: CC(CC1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3

IUPAC name: 3,3-diphenyl-N-(1-phenylpropan-2-yl)propan-1-amine

Also known as: B-436, Prenilamina, Prenylamine, Prenylamine lactate, PRENYLAMINE, PRENYLAMINE LACTATE, prenylamine

Parent form; salt/anhydrous children: CHEMBL1367944

Patent coverage: 755 distinct patent families (1,561 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 27 (assay-derived). Sample: Alpha-2C adrenergic receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Alpha-2B adrenergic receptor, Sodium channel protein type 5 subunit alpha, Voltage-gated L-type calcium channel, Sodium channel alpha subunits; brain (Types I, II, III), Beta-2 adrenergic receptor, Beta-1 adrenergic receptor, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Cannabinoid receptor 1, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Histamine H1 receptor, Mu-type opioid receptor, D(3) dopamine receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Kappa-type opioid receptor.

Bioactivity

ChEMBL activities: 29 potent at pChembl ≥ 5 of 32 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	7.19	IC50	65	nM	CHEMBL_ACT_15257968
P22002	6.68	Kd	209	nM	CHEMBL_ACT_1300806
SCN1A	6.52	IC50	300	nM	CHEMBL_ACT_388294
OPRK1	6.42	AC50	381.6	nM	CHEMBL_ACT_25129187
P62157	6.3	Kd	500	nM	CHEMBL_ACT_16568737
KCNH2	6.13	AC50	736	nM	CHEMBL_ACT_25117468
ADRA1A	6.06	AC50	876.6	nM	CHEMBL_ACT_25137775
HTR1A	6.02	AC50	957.1	nM	CHEMBL_ACT_25164422
O35505	5.91	IC50	1240	nM	CHEMBL_ACT_15257938
O35505	5.91	IC50	1240	nM	CHEMBL_ACT_15373275
ADRA2B	5.77	AC50	1700	nM	CHEMBL_ACT_25143440
P62157	5.75	Kd	1800	nM	CHEMBL_ACT_16567840
OPRM1	5.75	AC50	1800	nM	CHEMBL_ACT_25157268
SLC6A2	5.64	AC50	2300	nM	CHEMBL_ACT_25144738
ADRA2C	5.64	AC50	2300	nM	CHEMBL_ACT_25147607
P62157	5.62	EC50	2400	nM	CHEMBL_ACT_16568764
DRD3	5.62	AC50	2400	nM	CHEMBL_ACT_25193265
SCN5A	5.6	IC50	2520	nM	CHEMBL_ACT_15257909
DRD2	5.54	AC50	2900	nM	CHEMBL_ACT_25140064
GHSR	5.52	AC50	3000	nM	CHEMBL_ACT_25172498
HTR2A	5.47	AC50	3377	nM	CHEMBL_ACT_25173523
ADRB2	5.46	AC50	3500	nM	CHEMBL_ACT_25122670
P22002	5.37	AC50	4282	nM	CHEMBL_ACT_25119386
SLC6A3	5.33	AC50	4700	nM	CHEMBL_ACT_25123686
MC4R	5.19	AC50	6400	nM	CHEMBL_ACT_25184259
ADRB1	5.17	AC50	6800	nM	CHEMBL_ACT_25121518
SCN5A	5.15	AC50	7100	nM	CHEMBL_ACT_25158858
CNR1	5.1	AC50	7952	nM	CHEMBL_ACT_25181477
HRH1	5.1	AC50	7900	nM	CHEMBL_ACT_25212240

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).